<?xml version='1.0' encoding='utf-8'?>
<document id="11255075"><sentence text="Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors."><entity charOffset="14-23" id="DDI-PubMed.11255075.s1.e0" text="phenytoin" /><entity charOffset="85-94" id="DDI-PubMed.11255075.s1.e1" text="serotonin" /><pair ddi="false" e1="DDI-PubMed.11255075.s1.e0" e2="DDI-PubMed.11255075.s1.e0" /><pair ddi="false" e1="DDI-PubMed.11255075.s1.e0" e2="DDI-PubMed.11255075.s1.e1" /></sentence><sentence text="Several case reports have indicated that the selective serotonin re-uptake inhibitor (SSRI) fluoxetine increases phenytoin blood levels when given concurrently"><entity charOffset="55-64" id="DDI-PubMed.11255075.s2.e0" text="serotonin" /><entity charOffset="92-102" id="DDI-PubMed.11255075.s2.e1" text="fluoxetine" /><entity charOffset="113-122" id="DDI-PubMed.11255075.s2.e2" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.11255075.s2.e0" e2="DDI-PubMed.11255075.s2.e0" /><pair ddi="false" e1="DDI-PubMed.11255075.s2.e0" e2="DDI-PubMed.11255075.s2.e1" /><pair ddi="false" e1="DDI-PubMed.11255075.s2.e0" e2="DDI-PubMed.11255075.s2.e2" /><pair ddi="false" e1="DDI-PubMed.11255075.s2.e1" e2="DDI-PubMed.11255075.s2.e1" /><pair ddi="false" e1="DDI-PubMed.11255075.s2.e1" e2="DDI-PubMed.11255075.s2.e2" /></sentence><sentence text=" The mechanism of this drug-drug interaction has been attributed to inhibition of CYP2C9-catalyzed hydroxylation of phenytoin to its major oxidative metabolite in humans, para-hydroxyphenyl phenyl hydantoin (HPPH)"><entity charOffset="116-125" id="DDI-PubMed.11255075.s3.e0" text="phenytoin" /><entity charOffset="171-206" id="DDI-PubMed.11255075.s3.e1" text="para-hydroxyphenyl phenyl hydantoin" /><pair ddi="false" e1="DDI-PubMed.11255075.s3.e0" e2="DDI-PubMed.11255075.s3.e0" /><pair ddi="false" e1="DDI-PubMed.11255075.s3.e0" e2="DDI-PubMed.11255075.s3.e1" /></sentence><sentence text=" With a bank of human liver microsomes (HLM), four SSRIs (fluoxetine, norfluoxetine, sertraline, and paroxetine) were tested for inhibition of HPPH formation"><entity charOffset="58-68" id="DDI-PubMed.11255075.s4.e0" text="fluoxetine" /><entity charOffset="70-83" id="DDI-PubMed.11255075.s4.e1" text="norfluoxetine" /><entity charOffset="85-95" id="DDI-PubMed.11255075.s4.e2" text="sertraline" /><entity charOffset="101-111" id="DDI-PubMed.11255075.s4.e3" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.11255075.s4.e0" e2="DDI-PubMed.11255075.s4.e0" /><pair ddi="false" e1="DDI-PubMed.11255075.s4.e0" e2="DDI-PubMed.11255075.s4.e1" /><pair ddi="false" e1="DDI-PubMed.11255075.s4.e0" e2="DDI-PubMed.11255075.s4.e2" /><pair ddi="false" e1="DDI-PubMed.11255075.s4.e0" e2="DDI-PubMed.11255075.s4.e3" /><pair ddi="false" e1="DDI-PubMed.11255075.s4.e1" e2="DDI-PubMed.11255075.s4.e1" /><pair ddi="false" e1="DDI-PubMed.11255075.s4.e1" e2="DDI-PubMed.11255075.s4.e2" /><pair ddi="false" e1="DDI-PubMed.11255075.s4.e1" e2="DDI-PubMed.11255075.s4.e3" /><pair ddi="false" e1="DDI-PubMed.11255075.s4.e2" e2="DDI-PubMed.11255075.s4.e2" /><pair ddi="false" e1="DDI-PubMed.11255075.s4.e2" e2="DDI-PubMed.11255075.s4.e3" /></sentence><sentence text=" Initially, the K(m) and V(max) values of phenytoin hydroxylation to HPPH were determined in the individual HLM samples" /><sentence text=" The average K(m) (n=8) was 9" /><sentence text="7+/-2" /><sentence text="9 microM" /><sentence text=" The V(max) varied fivefold, with an average value of 113+/-53 pmol HPPH/min/nmol CYP450" /><sentence text=" All of the SSRIs inhibited HPPH formation; resulting Ki values were 31" /><sentence text="1+/-10" /><sentence text="1 microM (fluoxetine) (n=5), 51"><entity charOffset="10-20" id="DDI-PubMed.11255075.s12.e0" text="fluoxetine" /></sentence><sentence text="1+/-9" /><sentence text="4 microM (norfluoxetine) (n=3), 52"><entity charOffset="10-23" id="DDI-PubMed.11255075.s14.e0" text="norfluoxetine" /></sentence><sentence text="2+/-21" /><sentence text="5 microM (sertraline) (n=3), and 80" /><sentence text="0+/-7" /><sentence text="2 microM (paroxetine) (n=3)"><entity charOffset="10-20" id="DDI-PubMed.11255075.s18.e0" text="paroxetine" /></sentence><sentence text=" Sulfaphenazole (10 microM), utilized as a positive control for inhibition of HPPH formation, inhibited phenytoin hydroxylation (&gt;95%) in all HLM samples"><entity charOffset="1-15" id="DDI-PubMed.11255075.s19.e0" text="Sulfaphenazole" /></sentence><sentence text=" Diclofenac hydroxylation to 4'-OH diclofenac, a specific marker for CYP2C9 activity, was determined in HLM1-HLM6 and was highly correlated with HPPH formation in HLM1-HLM6, indicating that phenytoin hydroxylation in human liver microsomes is largely due to CYP2C9"><entity charOffset="1-11" id="DDI-PubMed.11255075.s20.e0" text="Diclofenac" /><entity charOffset="190-199" id="DDI-PubMed.11255075.s20.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.11255075.s20.e0" e2="DDI-PubMed.11255075.s20.e0" /><pair ddi="false" e1="DDI-PubMed.11255075.s20.e0" e2="DDI-PubMed.11255075.s20.e1" /></sentence><sentence text=" This work presents direct evidence that the effect of fluoxetine on phenytoin blood levels may be explained by inhibition of CYP2C9-catalyzed phenytoin hydroxylation"><entity charOffset="55-65" id="DDI-PubMed.11255075.s21.e0" text="fluoxetine" /><entity charOffset="69-78" id="DDI-PubMed.11255075.s21.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.11255075.s21.e0" e2="DDI-PubMed.11255075.s21.e0" /><pair ddi="false" e1="DDI-PubMed.11255075.s21.e0" e2="DDI-PubMed.11255075.s21.e1" /></sentence><sentence text=" In light of typical SSRI blood levels observed in patients, this study also suggests that the risk of a SSRI-phenytoin interaction is highest with fluoxetine and norfluoxetine, and less likely with sertraline and paroxetine"><entity charOffset="105-119" id="DDI-PubMed.11255075.s22.e0" text="SSRI-phenytoin" /><entity charOffset="148-158" id="DDI-PubMed.11255075.s22.e1" text="fluoxetine" /><entity charOffset="163-176" id="DDI-PubMed.11255075.s22.e2" text="norfluoxetine" /><entity charOffset="199-209" id="DDI-PubMed.11255075.s22.e3" text="sertraline" /><entity charOffset="214-224" id="DDI-PubMed.11255075.s22.e4" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e0" e2="DDI-PubMed.11255075.s22.e0" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e0" e2="DDI-PubMed.11255075.s22.e1" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e0" e2="DDI-PubMed.11255075.s22.e2" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e0" e2="DDI-PubMed.11255075.s22.e3" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e0" e2="DDI-PubMed.11255075.s22.e4" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e1" e2="DDI-PubMed.11255075.s22.e1" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e1" e2="DDI-PubMed.11255075.s22.e2" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e1" e2="DDI-PubMed.11255075.s22.e3" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e1" e2="DDI-PubMed.11255075.s22.e4" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e2" e2="DDI-PubMed.11255075.s22.e2" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e2" e2="DDI-PubMed.11255075.s22.e3" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e2" e2="DDI-PubMed.11255075.s22.e4" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e3" e2="DDI-PubMed.11255075.s22.e3" /><pair ddi="false" e1="DDI-PubMed.11255075.s22.e3" e2="DDI-PubMed.11255075.s22.e4" /></sentence><sentence text="" /></document>